Popular on EntSun
- Nieves Ministries Leads with Faith to Fortify Safety, Education, and Puerto Rican Culture in Colorado - 191
- Global Patient Organizations Applaud Historic Passage of a Resolution at WHA 78: "Skin diseases as a global public health priority" - 186
- Beverly D'Angelo, Eric Roberts, Jefferson White, Keith David Lend Star Power to 15th Art of Brooklyn Film Festival - 182
- Introducing Nene Wear: The Bold, Sporty Fashion Brand by Jeanne Myrick, Powered by KLM Enterprises - 164
- San Francisco Hometown Star Terri J. Vaughn Hits Streaming Highs in Tyler Perry Studios "She the People" on Netflix - 155
- Juventix Regenerative Medical Announces Strategic Partnership with Juvasonic® to Expand Needle-Free Biologic Delivery Platform - 155
- Detroit Grand Prix High Profile Media Exposure, $100 Million Financing for Major Acquisition & Growth Strategy; Remote Lottery Platform: Lottery.com - 152
- Prymax Media & Technology Group Acquires 'Hidden Treasures' From Estate of Jewel Records Founder Stan Lewis - 144
- RockNTix Announces Strategic Partnership with Microsoft to Power Next-Gen Event Ticketing Platform - 141
- Global Patient Organizations Applaud Historic Passage of Integrated Lung Health Resolution at World Health Assembly 78 - 132
Similar on EntSun
- Dr. Jacqueline West Honored as Best Dentist in JAX by Folio Weekly
- Exciting News: Pivotal Health Solutions Acquires Revolutionary Portable Parallel Bars
- Mensa Foundation Prize Awarded to Neuroscientist-Pianist
- OPRAH.COM Featured Award-Winning Novel AS FAR AS YOU GO BEFORE YOU HAVE TO COME BACK now Available as Audiobook
- purelyIV Blog Named One of the Top 45 IV Therapy Blogs by Feedspot
- purelyIV Launches Mobile Iron Infusion Therapy for Patients with Iron Deficiency Anemia
- Smile Makers Dental Care Introduces FP1: East Bay's First Robotic-Assisted Full-Arch Implant Solution for Natural, Fixed Smiles
- Fray Fitness and Truemed Partner to Enable HSA/FSA-Funded Fitness Equipment Purchases
- Sploot Vets and DeepScan Launch Exclusive Regional U.S. Partnership to Bring Breakthrough Pet DNA Test to Market
- As Sober.Buzz Community Explodes It's Growth Globally it is Announcing "Spreading the Good BUZZ" Podcast Hosted by Josh Case Debuting July 7th
Investor Workshop at Mar-A-Lago, $27 Million for Acquisitions and Drug Treatment of Suicidal Depression: NRx Pharmaceuticals, Inc. (Stock S: NRXP)
EntSun News/11047019
$NRXP $31 Price Target from Respected Investment Analyst D. Boral Capital
MIAMI - EntSun -- Developing NRX-101, an FDA-Designated Investigational Breakthrough Therapy for Suicidal Treatment-Resistant Bipolar Depression and Chronic Pain.
Aiming to be the First FDA-Approved Medication to Treat Suicidal Depression
Designed to Help Address the Needs of Over 13 Million Americans who Seriously Consider Suicide Each Year (CDC).
Binding Term Sheet for $27 Million in Funding for HOPE Clinic Acquisitions and Pharmaceutical Operations
Kadima Neuropsychiatry Institute Targeted as First Acquisition for HOPE Subsidiary International Network of Interventional Psychiatry Clinics.
Completion of NDA Filing Expected in First Quarter of 2025
NRx Pharmaceuticals, Inc. (Stock Symbol: NRXP) is a clinical-stage biopharmaceutical company developing therapeutics based on its NMDA platform for the treatment of central nervous system disorders, specifically suicidal bipolar depression, chronic pain and PTSD. NRXP is developing NRX-101, an FDA-designated investigational Breakthrough Therapy for suicidal treatment-resistant bipolar depression and chronic pain
NRXP has partnered with Alvogen Pharmaceuticals around the development and marketing of NRX-101 for the treatment of suicidal bipolar depression. NRX-101 additionally has potential to act as a non-opioid treatment for chronic pain, as well as a treatment for complicated UTI.
NRXP is working on a New Drug Application for NRX-100 (IV ketamine) in the treatment of suicidal depression, based on results of well-controlled clinical trials conducted under the auspices of the US National Institutes of Health and newly obtained data from French health authorities, licensed under a data sharing agreement. NRXP was awarded Fast Track Designation for development of ketamine (NRX-100) by the US FDA as part of a protocol to treat patients with acute suicidality.
Intravenous ketamine is widely accepted as a standard of care for acute treatment of suicidal depression, in the absence of an FDA-labeled product; the only treatment currently approved by the FDA is electroconvulsive therapy (ECT). According to the CDC, 3.8 million Americans make a plan for suicide each year. This represents a $3-5 billion market at expected pricing. Based on the data in the trials referenced above, the Company's regulatory counsel encouraged the Company to file an NDA for suicidal depression for NRX-100.
More on EntSun News
In a January 2025 report, respected investment analysis firm D. Boral Capital assigned NRXP a $31 Price Target. The full report may be viewed at this link:
https://www.nrxpharma.com/wp-content/uploads/2025/01/HOPE-Therapeutics-Advances-With-Kadima.pdf.
Investor Workshop at the Mar-A-Lago Club
On January 10th NRXP announced it conducted an investor workshop to support planned expansion of subsidiary HOPE's network of interventional psychiatry practices focused on the treatment of suicidal depression and PTSD, at the Mar-A-Lago Club in Palm Beach, FL.
The event was attended by Qualified Institutional Buyers as defined by the Securities and Exchange Commission and included Jonathan Javitt, MD, MPH, Chairman and CEO of NRXP together with Dallas Sauer, Founder of Smith and Sauer, the private investment firm that recently committed to invest in both NRXP and HOPE.
Key areas of investor discussions included:
NRXP HOPE's mission to build an international network of best-in class, EBITDA positive, interventional psychiatry clinics
$25 million financing committed by Smith and Sauer (JGS Holdings LLC) to leverage anticipated bank financing projected to secure $100 million in HOPE clinic revenue stream on a pro-forma basis
Recently announced progress for NRXP HOPE's initial clinic acquisitions
Potential mechanisms for follow-on non-dilutive financing to expand NRXP HOPE's network by an additional 50 clinics in 2026 and 100 clinics in 2027
NRXP has been invited to return to Mar-A-Lago for an expanded meeting during the last week of January that will include both Qualified Institutional Buyers and Accredited Investors.
Binding Term Sheet for $27 Million in Funding for HOPE Clinic Acquisitions and Pharmaceutical Operations
On January 6th NRXP announced signing of a Binding Term Sheet with Smith & Sauer, LLC, for $25 million equity purchases to fund planned HOPE clinic subsidiary acquisitions. Company management anticipates this new capital in combination with anticipated bank and/or bond lending, to be sufficient to drive substantial revenue in HOPE clinic acquisition during 2025. An additional $2 million equity investment in NRXP will be used to advance the Company's new drug applications for NRX-100 and NRX-101.
Benefits of this agreement include:
More on EntSun News
Anticipated capital from funds managed by Smith & Sauer to augment potential bank-financing for acquisition of HOPE Therapeutics clinics and support NRXP operations.
Purchase of $25 million in Series A Preferred Stock in HOPE Therapeutics (non-dilutive to NRXP shareholders) convertible into 1/3 of fully diluted HOPE Therapeutics equity, with a 15% current preferred dividend (non-callable for 2 years) for planned HOPE clinic acquisitions.
Purchase $2 million in NRXP equity, above the most recent closing price, at $2.75 per share. Investor will also purchase 500,000 NRXP shares from existing shareholders for $2.75 per share
In connection with both investments, investor shall receive warrants to purchase 3 million currently unregistered shares of NRXP common stock at $3.00 per share with a 24-month term.
Smith & Sauer will also be entitled to receive royalties on net revenues from NRXP product sales to a defined rate of return
Investment in HOPE Therapeutics is expected to enhance the NRXP balance sheet value, strengthening its financial position.
Smith & Sauer to join the HOPE Therapeutics and NRx Pharmaceuticals' Boards of Directors
Kadima Neuropsychiatry Institute Expected First Acquisition for HOPE Subsidiary International Network of Interventional Psychiatry Clinics
On January 2nd NRXP announced the planned acquisition of the Kadima Neuropsychiatry Institute of La Jolla, CA, per the previously announced Letter of Intent, for the Company's HOPE subsidiary network. Kadima is expected to serve as the flagship clinic for HOPE's planned international network of interventional psychiatry clinics, designed to provide advanced treatments for debilitating diseases such as depression, anxiety and PTSD.
Initial Section of U.S. New Drug Application to the FDA for NRX-100 (IV Ketamine) for the Treatment of Suicidal Depression
On December 30th NRXP announced the transmission of first section of its New Drug Application (NDA) for NRX-100 (ketamine) for electronic filing with the U.S. Food & Drug Administration (FDA). NRX-100 was initially granted Fast Track Designation in 2017 for use in combination with NRX-101 (D-cycloserine/lurasidone) for treatment of suicidal bipolar depression.
For more information on $NRXP visit: https://www.nrxpharma.com/ and https://compasslivemedia.com/case-study/nrx-pharmaceuticals/
Media Contact
Company Name: NRx Pharmaceuticals, Inc. (Stock Symbol: NRXP)
Contact Person: Matthew Duffy, Chief Business Officer
Company Website: https://www.nrxpharma.com/
Email: mduffy@nrxpharma.com
Phone: (484) 254-6134
Home Country: United States
DISCLAIMER: https://corporateads.com/disclaimer/
Disclosure listed on the CorporateAds website
Aiming to be the First FDA-Approved Medication to Treat Suicidal Depression
Designed to Help Address the Needs of Over 13 Million Americans who Seriously Consider Suicide Each Year (CDC).
Binding Term Sheet for $27 Million in Funding for HOPE Clinic Acquisitions and Pharmaceutical Operations
Kadima Neuropsychiatry Institute Targeted as First Acquisition for HOPE Subsidiary International Network of Interventional Psychiatry Clinics.
Completion of NDA Filing Expected in First Quarter of 2025
NRx Pharmaceuticals, Inc. (Stock Symbol: NRXP) is a clinical-stage biopharmaceutical company developing therapeutics based on its NMDA platform for the treatment of central nervous system disorders, specifically suicidal bipolar depression, chronic pain and PTSD. NRXP is developing NRX-101, an FDA-designated investigational Breakthrough Therapy for suicidal treatment-resistant bipolar depression and chronic pain
NRXP has partnered with Alvogen Pharmaceuticals around the development and marketing of NRX-101 for the treatment of suicidal bipolar depression. NRX-101 additionally has potential to act as a non-opioid treatment for chronic pain, as well as a treatment for complicated UTI.
NRXP is working on a New Drug Application for NRX-100 (IV ketamine) in the treatment of suicidal depression, based on results of well-controlled clinical trials conducted under the auspices of the US National Institutes of Health and newly obtained data from French health authorities, licensed under a data sharing agreement. NRXP was awarded Fast Track Designation for development of ketamine (NRX-100) by the US FDA as part of a protocol to treat patients with acute suicidality.
Intravenous ketamine is widely accepted as a standard of care for acute treatment of suicidal depression, in the absence of an FDA-labeled product; the only treatment currently approved by the FDA is electroconvulsive therapy (ECT). According to the CDC, 3.8 million Americans make a plan for suicide each year. This represents a $3-5 billion market at expected pricing. Based on the data in the trials referenced above, the Company's regulatory counsel encouraged the Company to file an NDA for suicidal depression for NRX-100.
More on EntSun News
- Dr. Jacqueline West Honored as Best Dentist in JAX by Folio Weekly
- Buffalo Producer The MarTian SMG Earns 5x Gold Certification for Key Glock's "Dirt"
- Exciting News: Pivotal Health Solutions Acquires Revolutionary Portable Parallel Bars
- Nick Menza Documentary "This Was My Life" now on Blu-ray!
- Miboxer Achieved New Goal in GILE 2025
In a January 2025 report, respected investment analysis firm D. Boral Capital assigned NRXP a $31 Price Target. The full report may be viewed at this link:
https://www.nrxpharma.com/wp-content/uploads/2025/01/HOPE-Therapeutics-Advances-With-Kadima.pdf.
Investor Workshop at the Mar-A-Lago Club
On January 10th NRXP announced it conducted an investor workshop to support planned expansion of subsidiary HOPE's network of interventional psychiatry practices focused on the treatment of suicidal depression and PTSD, at the Mar-A-Lago Club in Palm Beach, FL.
The event was attended by Qualified Institutional Buyers as defined by the Securities and Exchange Commission and included Jonathan Javitt, MD, MPH, Chairman and CEO of NRXP together with Dallas Sauer, Founder of Smith and Sauer, the private investment firm that recently committed to invest in both NRXP and HOPE.
Key areas of investor discussions included:
NRXP HOPE's mission to build an international network of best-in class, EBITDA positive, interventional psychiatry clinics
$25 million financing committed by Smith and Sauer (JGS Holdings LLC) to leverage anticipated bank financing projected to secure $100 million in HOPE clinic revenue stream on a pro-forma basis
Recently announced progress for NRXP HOPE's initial clinic acquisitions
Potential mechanisms for follow-on non-dilutive financing to expand NRXP HOPE's network by an additional 50 clinics in 2026 and 100 clinics in 2027
NRXP has been invited to return to Mar-A-Lago for an expanded meeting during the last week of January that will include both Qualified Institutional Buyers and Accredited Investors.
Binding Term Sheet for $27 Million in Funding for HOPE Clinic Acquisitions and Pharmaceutical Operations
On January 6th NRXP announced signing of a Binding Term Sheet with Smith & Sauer, LLC, for $25 million equity purchases to fund planned HOPE clinic subsidiary acquisitions. Company management anticipates this new capital in combination with anticipated bank and/or bond lending, to be sufficient to drive substantial revenue in HOPE clinic acquisition during 2025. An additional $2 million equity investment in NRXP will be used to advance the Company's new drug applications for NRX-100 and NRX-101.
Benefits of this agreement include:
More on EntSun News
- Ali Siddiq - Comedian / Master Storyteller Adds 34 More Dates To His 2025
- Jeopardy!'s Ken Jennings Headlines National Mensa Event
- Mensa Foundation Prize Awarded to Neuroscientist-Pianist
- New book, "High-Tech Heroes," redefines billionaire as someone who improves a billion lives
- From Marvel to Meaning: Actor Stanley Aughtry Redefines Legacy in Hollywood and Beyond
Anticipated capital from funds managed by Smith & Sauer to augment potential bank-financing for acquisition of HOPE Therapeutics clinics and support NRXP operations.
Purchase of $25 million in Series A Preferred Stock in HOPE Therapeutics (non-dilutive to NRXP shareholders) convertible into 1/3 of fully diluted HOPE Therapeutics equity, with a 15% current preferred dividend (non-callable for 2 years) for planned HOPE clinic acquisitions.
Purchase $2 million in NRXP equity, above the most recent closing price, at $2.75 per share. Investor will also purchase 500,000 NRXP shares from existing shareholders for $2.75 per share
In connection with both investments, investor shall receive warrants to purchase 3 million currently unregistered shares of NRXP common stock at $3.00 per share with a 24-month term.
Smith & Sauer will also be entitled to receive royalties on net revenues from NRXP product sales to a defined rate of return
Investment in HOPE Therapeutics is expected to enhance the NRXP balance sheet value, strengthening its financial position.
Smith & Sauer to join the HOPE Therapeutics and NRx Pharmaceuticals' Boards of Directors
Kadima Neuropsychiatry Institute Expected First Acquisition for HOPE Subsidiary International Network of Interventional Psychiatry Clinics
On January 2nd NRXP announced the planned acquisition of the Kadima Neuropsychiatry Institute of La Jolla, CA, per the previously announced Letter of Intent, for the Company's HOPE subsidiary network. Kadima is expected to serve as the flagship clinic for HOPE's planned international network of interventional psychiatry clinics, designed to provide advanced treatments for debilitating diseases such as depression, anxiety and PTSD.
Initial Section of U.S. New Drug Application to the FDA for NRX-100 (IV Ketamine) for the Treatment of Suicidal Depression
On December 30th NRXP announced the transmission of first section of its New Drug Application (NDA) for NRX-100 (ketamine) for electronic filing with the U.S. Food & Drug Administration (FDA). NRX-100 was initially granted Fast Track Designation in 2017 for use in combination with NRX-101 (D-cycloserine/lurasidone) for treatment of suicidal bipolar depression.
For more information on $NRXP visit: https://www.nrxpharma.com/ and https://compasslivemedia.com/case-study/nrx-pharmaceuticals/
Media Contact
Company Name: NRx Pharmaceuticals, Inc. (Stock Symbol: NRXP)
Contact Person: Matthew Duffy, Chief Business Officer
Company Website: https://www.nrxpharma.com/
Email: mduffy@nrxpharma.com
Phone: (484) 254-6134
Home Country: United States
DISCLAIMER: https://corporateads.com/disclaimer/
Disclosure listed on the CorporateAds website
Source: Corporate Ads
0 Comments
Latest on EntSun News
- Crazy Discount Codes App Transforms Mobile Shopping With Real-Time Deals
- Sploot Vets and DeepScan Launch Exclusive Regional U.S. Partnership to Bring Breakthrough Pet DNA Test to Market
- La'Nardo Myrick Sr Announces 9.0 Magazine Migrates from MagCloud to Kindle Direct Publishing
- As Sober.Buzz Community Explodes It's Growth Globally it is Announcing "Spreading the Good BUZZ" Podcast Hosted by Josh Case Debuting July 7th
- Coming Soon: The Cottages at Powell Park Offer a Rare Blend of Charm, Convenience, and Community in Raleigh
- Musica by BGE Purges 102,000 Foreign Accounts in National Security Move
- CredHub and All County Property Management Franchise Corp. Partner to Empower Franchisees with Rental Payment Credit Reporting Solutions
- Pregis Shares 2024 Sustainability Report Highlighting Progress in Circular Product Innovation, Emissions Accountability, and Global Impact
- Florida Boat & Fishing Digital Magazine Launches Ad Campaign for 2025 with Unparalleled Reach
- It's Summertime and the SLAYING is Easy: GNOME SICK: 7 SLAYS TIL MITHRAS
- Initial Order Received from Vietnamese Maritime Security and Defense Services for Advanced Video Compression Solution: RMX; Stock Symbol: RMXI
- Tune In. Turn Up. Take Over: The Pulse of SMN Radio
- Keebos Launches New Universal Pearl Strap That Attaches to Any Phone Case
- Work 365 Launches Certified Provider Integration (CPI) Program to Help Distributors and CSPs Navigate Microsoft's Evolving Ecosystem
- Fysin Hair Launches New Affordable Lace Front Wig Collection for Fashion-Forward Look
- Indie Band Run Downhill To Release "the Rattler" From Grammy® Winner T.j. Troy June 27th
- Five Aster Awards! Fusion Marketing Group Brings Home Big Wins in 2025!
- Comedy Under The Stars: Comedian Don Barnhart Brings His Hilarious Show To Maui's Tropical Paradise!
- Entertainment Events Brings Two Laugh-Out-Loud Shows to New Spire Arts
- Pride Takes Center Stage in Ghostlight Ensemble Theatre Co's 9th Season